

## DAFTAR PUSTAKA

- Abdel-Misih, S. and Bloomston, M., 2010. Liver Anatomy. *Surgical Clinics of North America*, 90(4), pp.643-653.
- Abrão Ferreira, P. and Tenore, S., 2010. Response predictors to treatment with pegylated interferon in chronic hepatitis B. *The Brazilian Journal of Infectious Diseases*, 14(5), pp.519-525.
- Amarapurkar, Deepak. "Management of hepatitis B viral infection with normal ALT." *Hepatitis B Annual*, vol. 3, no. 1, 2006. Accessed 21 February 2019.
- Andreani, T., Serfaty, L., Mohand, D., Dernaika, S., Wendum, D., Chazouillères, O. and Poupon, R., 2007. Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. *Clinical Gastroenterology and Hepatology*, 5(5), pp.636-641.
- Bonino, F., Brunetto, M., Rizzetto, M. and Will, H., 1991. Hepatitis B virus unable to secrete E antigen. *Gastroenterology*, 100(4), pp.1138-1141.
- Braet, F. and Wisse, E., 2002. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. *Comparative Hepatology*, 1(1), p.1.
- Brunetto, M., Moriconi, F., Bonino, F., Lau, G., Farci, P., Yurdaydin, C., Piratvisuth, T., Luo, K., Wang, Y., Hadziyannis, S., Wolf, E., McCloud, P., Batrla, R. and Marcellin, P., 2008. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. *Hepatology*, 49(4), pp.1141-1150.
- Brunetto, M., 2010. A new role for an old marker, HBsAg. *Journal of Hepatology*, 52(4), pp.475-477.
- cdc.gov. 2006. *Hepatitis B Vaccination Coverage Among Adults*. [online] Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5518a3.htm> [Accessed 11 April 2020].
- CEVHAP, 2020. *Situation Analysis Of Viral Hepatitis In Indonesia*. [online] Available at: <http://www.cevhap.org/index.php/en/> [Accessed 25 March 2020].
- Chang, M. and Liaw, Y., 2014. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. *Journal of Hepatology*, 61(6), pp.1407-1417.
- Chen, Y., Huang, S., Chu, C. and Liaw, Y., 2011. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. *Journal of Viral Hepatitis*, 19(2), pp.138-146.

- Chen, X., Mao, Q., Xie, Y., Dou, X., Xie, Q., Sheng, J., Gao, Z., Zhou, X., Liu, Y., Zheng, H., Zhang, S., Li, S., Zhu, F., Xu, Y., Zhang, M., Hu, Y., Chen, X., Huang, Y., Ren, H. and Jia, J., 2019. *A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2A*.
- Chisari, F., 1995. Hepatitis B virus transgenic mice: Insights into the virus and the disease. *Hepatology*, 22(4), pp.1316-1325.
- Chisari, F., Isogawa, M. and Wieland., S. (2010). Pathogenesis of hepatitis B virus infection. *Pathologie Biologie*, 58(4), pp.258-266.
- Chuaypen, N., Posuwan, N., Chittmittraprap, S., Hirankarn, N., Treeprasertsuk, S., Tanaka, Y., Shinkai, N., Poovorawan, Y. and Tangkijvanich, P., 2018. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. *Clinical Microbiology and Infection*, 24(3), pp.306.e7-306.e13.
- Conjeevaram, H. and Lok, A., 2003. Management of chronic hepatitis B. *Journal of Hepatology*, 38, pp.90-103.
- Dan, Y., Aung, M. and Lim, S., 2008. The economics of treating chronic hepatitis B in Asia. *Hepatology International*, 2(3), pp.284-295.
- D'Souza, R. and Foster, G., 2004. Diagnosis and treatment of chronic hepatitis B. *JRSM*, 97(7), pp.318-321.
- Ferrari, C., Missale, G., Boni, C. and Urbani, S., 2003. Immunopathogenesis of hepatitis B. *Journal of Hepatology*, 39, pp.36-42.
- Fung, S., Chae, H., Fontana, R., Conjeevaram, H., Marrero, J., Oberhelman, K., Hussain, M. and Lok, A., 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. *Journal of Hepatology*, 44(2), pp.283-290.
- Guclu, E., Ogutlu, A. and Karabay, O., 2016. A Study on the Age-Related Changes in Hepatitis B and C Virus Serology. *The Eurasian Journal of Medicine*, 48(1), pp.37-41.
- Gunal, O., Barut, S., Etikan, I., Duygu, F., Tuncel, U. and Sunbul, M. (2015). Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection. *The Turkish Journal of Gastroenterology*, 25(1), pp.142-146.
- Han, K. and Kim, D., 2008. Chronic HBV infection with persistently normal ALT b. not to treat. *Hepatology International*, 2(2), pp.185-189.
- Hou, J., Wang, G., Wang, F., Cheng, J., Ren, H., Zhuang, H., Sun, J., Li, L., Li, J., Meng, Q., Zhao, J., Duan, Z., Jia, J., Tang, H., Sheng, J., Peng, J., Lu, F., Xie, Q. and Wei, L., 2017. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). *Journal of Clinical and Translational Hepatology*, 5(4), pp.297-318.

- Hsu, Y., Chien, R., Yeh, C., Sheen, I., Chiou, H., Chu, C. and Liaw, Y., 2002. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. *Hepatology*, 35(6), pp.1522-1527.
- Hu, P., Shang, J., Zhang, W., Gong, G., Li, Y., Chen, X., Jiang, J., Xie, Q., Dou, X., Sun, Y., Li, Y., Liu, Y., Liu, G., Mao, D., Chi, X., Tang, H., Li, X., Xie, Y., Chen, X., Jiang, J., Zhao, P., Hou, J., Gao, Z., Fan, H., Ding, J., Zhang, D. and Ren, H., 2018. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. *Journal of Clinical and Translational Hepatology*, 6(1), pp.1-10.
- Iloeje, U., Yang, H., Su, J., Jen, C., You, S. and Chen, C., 2006. Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. *Gastroenterology*, 130(3), pp.678-686.
- Janssen, H., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U., Cakaloglu, Y., Simon, C., So, T., Gerken, G., de Man, R., Niesters, H., Zondervan, P., Hansen, B. and Schalm, S., 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *The Lancet*, 365(9454), pp.123-129.
- Journal of Hepatology*, 2012. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. 57(1), pp.167-185.
- Kranidioti, H., Manolakopoulos, S., & Khakoo, S. I. (2015). Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. *Annals of gastroenterology*, 28(2), 173–181.
- Krajden, M., McNabb, G., & Petric, M. (2005). The laboratory diagnosis of hepatitis B virus. *The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale*, 16(2), 65–72. doi:10.1155/2005/450574
- Kolou, M., Katawa, G., Salou, M., Gozo-Akakpo, K., Dossim, S., Kwarteng, A. and Prince-David, M., 2017. High Prevalence of Hepatitis B Virus Infection in the Age Range of 20-39 Years Old Individuals in Lome. *The Open Virology Journal*, 11(1), pp.1-7.
- Kuhns, M. and Busch, M., 2006. New Strategies for Blood Donor Screening for Hepatitis B Virus. *Molecular Diagnosis & Therapy*, 10(2), pp.77-91.
- Kwon, S. and Lee, C. (2011). Epidemiology and prevention of hepatitis B virus infection. *The Korean Journal of Hepatology*, 17(2), p.87.
- Lai, M., Hyatt, B., Nasser, I., Curry, M. and Afdhal, N., 2007. The clinical significance of persistently normal ALT in chronic hepatitis B infection. *Journal of Hepatology*, 47(6), pp.760-767.
- Lampertico P, Messinger D, Oladipupo H, Bakalos G, Asselah T. An easy to use baseline score to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings. Presented at EASL, Barcelona, Spain, 2016

- Lampertico, P. and Viganò, M., 2012. Clinical implications of HBsAg quantification in patients with chronic hepatitis B. *Saudi Journal of Gastroenterology*, 18(2), p.81.
- Lampertico, P., Viganò, M. and Colombo, M., 2011. Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. *Liver International*, 31, pp.90-94.
- Lau, G., Piratvisuth, T., Luo, K., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M., Chow, W., Paik, S., Chang, W., Berg, T., Flisiak, R., McCloud, P. and Pluck, N. (2005). Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. *New England Journal of Medicine*, 352(26), pp.2682-2695.
- Liang, T. (2009). Hepatitis B: The virus and disease. *Hepatology*, 49(S5), pp.S13-S21.
- Liaw, Y. (2009). HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. *Hepatology International*, 3(3), pp.425-433.
- Lok, A. and Lai, C., 1990. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. *Journal of Hepatology*, 10(1), pp.29-34.
- Lok, A. and McMahon, B. (2007). Chronic hepatitis B. *Hepatology*, 45(2), pp.507-539.
- Lusida, M., Juniastuti and Yano, Y. (2016). Current hepatitis B virus infection situation in Indonesia and its genetic diversity. *World Journal of Gastroenterology*, 22(32), p.7264.
- MacLachlan, J. and Cowie, B. (2015). Hepatitis B Virus Epidemiology. *Cold Spring Harbor Perspectives in Medicine*, 5(5), pp.a021410-a021410.
- Manesis, E., 2003. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. *The American Journal of Gastroenterology*, 98(10), pp.2261-2267.
- Mellerup, M., Krogsgaard, K., Mathurin, P., Glud, C. and Poynard, T., 2002. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. *The Cochrane Database of Systematic Reviews*,
- Mendy, M., Peterson, I., Hossin, S., Peto, T., Jobarteh, M., Jeng-Barry, A., Sidibeh, M., Jatta, A., Moore, S., Hall, A. and Whittle, H., 2013. Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster Dose. *PLoS ONE*, 8(3), p.e58029.
- Moucari, R., Mackiewicz, V., Lada, O., Ripault, M., Castelnau, C., Martinot-Peignoux, M., Dauvergne, A., Asselah, T., Boyer, N., Bedossa, P., Valla, D., Vidaud, M., Nicolas-Chanoine, M. and Marcellin, P., 2008. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated

- interferon alfa-2a in HBeAg-negative patients. *Hepatology*, 49(4), pp.1151-1157.
- Muljono, D., Wijayadi, T. and Sjahril, R. (2018). Hepatitis B Virus Infection among Health Care Workers in Indonesia. *Euroasian Journal of Hepato-Gastroenterology*, 8(1), pp.88-92.
- Muljono, D. (2017). Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian Journal of Hepato-Gastroenterology*, 7(1), pp.55-59.
- Mulyanto (2016). Viral Hepatitis in Indonesia: Past, Present, and Future. *Euroasian journal of hepato-gastroenterology*, 6(1), 65–69. doi:10.5005/jp-journals-10018-1171
- NC Hepatitis B Public Health Program Manual, 2012. Interpretation of Hepatitis B serology, viewed 26 May 2019, [https://epi.publichealth.nc.gov/cd/lhds/manuals/hepB/docs/hbv\\_serology.pdf](https://epi.publichealth.nc.gov/cd/lhds/manuals/hepB/docs/hbv_serology.pdf)
- nhs.uk. 2020. *Hepatitis B*. [online] Available at: <<https://www.nhs.uk/conditions/hepatitis-b/>> [Accessed 6 August 2020].
- Niro, G. A., Ciancio, A. , Gaeta, G. B., Smedile, A. , Marrone, A. , Olivero, A. , Stanzione, M. , David, E. , Brancaccio, G. , Fontana, R. , Perri, F. , Andriulli, A. and Rizzetto, M. (2006), Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. *Hepatology*, 44: 713-720. doi:10.1002/hep.21296
- Ozaras, R., Tabak, F., Tahan, V., Ozturk, R., Akin, H., Mert, A. and Senturk, H., 2008. Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment. *Digestive Diseases and Sciences*, 53(11), pp.2995-2998.
- Pallier, C., Castéra, L., Soulier, A., Hézode, C., Nordmann, P., Dhumeaux, D. and Pawlotsky, J., 2006. Dynamics of Hepatitis B Virus Resistance to Lamivudine. *Journal of Virology*, 80(2), pp.643-653.
- Papatheodoridis, G., Manolakopoulos, S., Liaw, Y. and Lok, A., 2012. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. *Journal of Hepatology*, 57(1), pp.196-202.
- Perhimpunan Peneliti Hati Indonesia (PPHI), 2017. Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia. Jakarta: Perhimpunan Peneliti Hati Indonesia
- Perrillo, R., 2001. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. *Gastroenterology*, 120(4), pp.1009-1022.
- Perrillo, R. (2009). Benefits and risks of interferon therapy for hepatitis B. *Hepatology*, 49(S5), pp.S103-S111.
- Poddar, U., Yachha, S., Agarwal, J. and Krishnani, N., 2012. Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo

- therapy with lamivudine and interferon?. *Journal of Viral Hepatitis*, 20(5), pp.311-316.
- Purwono, P., Yano, Y., Utsumi, T., Wahyuni, R., Juniasuti, Soetjipto, Hayashi, Y., Bramanthi, R., Amin, M., Lusida, M., Resi, E., Hotta, H. and Nursidah, 2016. Hepatitis B Virus Infection in Indonesia 15 Years After Adoption of a Universal Infant Vaccination Program: Possible Impacts of Low Birth Dose Coverage and a Vaccine-Escape Mutant. *The American Journal of Tropical Medicine and Hygiene*, 95(3), pp.674-679.
- Pusdatin Kemenkes RI. (2014) *Situasi dan Analisis Hepatitis*. Jakarta: Kementerian Kesehatan RI
- Rosenberg, W., 1999. Mechanisms of immune escape in viral hepatitis. *Gut*, 44(5), pp.759-764.
- Seeger, C. and Mason, W., 2000. Hepatitis B Virus Biology. *Microbiology and Molecular Biology Reviews*, 64(1), pp.51-68.
- Stratton, K., Ford, A., Rusch, E., Clayton, E., Vaccines, C. and Medicine, I. (2019). *Hepatitis B Vaccine*. [online] Ncbi.nlm.nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK190035/> [Accessed 12 Jun. 2019].
- Tamai, H., Ida, Y., Shingaki, N., Shimizu, R., Fukatsu, K., Itonaga, M., Yoshida, T., Maeda, Y., Moribata, K., Maekita, T., Iguchi, M., Kato, J. and Kitano, M. (2017). Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir. *Hepatitis Research and Treatment*, 2017, pp.1-7.
- Tan, G., Song, H., Xu, F. and Cheng, G., 2018. When Hepatitis B Virus Meets Interferons. *Frontiers in Microbiology*, 9.
- ter Borg, M., van Zonneveld, M., Zeuzem, S., Senturk, H., Akarca, U., Simon, C., Hansen, B., Haagmans, B., de Man, R., Schalm, S. and Janssen, H., 2006. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. *Hepatology*, 44(3), pp.721-727.
- Terrault, N., Lok, A., McMahon, B., Chang, K., Hwang, J., Jonas, M., Brown, R., Bzowej, N. and Wong, J., 2018. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*, 67(4), pp.1560-1599.
- Torre, D. and Tambini, R., 1996. Interferon- Therapy for Chronic Hepatitis B in Children: A Meta-Analysis. *Clinical Infectious Diseases*, 23(1), pp.131-137.
- Tortora, G., 2009. *Principles Of Anatomy And Physiology*.
- Tseng, T. and Kao, J., 2012. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. *Journal of Gastroenterology*, 48(1), pp.13-21.
- Tseng, T., Liu, C., Yang, H., Su, T., Wang, C., Chen, C., Kuo, S., Liu, C., Chen, P., Chen, D. and Kao, J., 2012. High Levels of Hepatitis B Surface Antigen

- Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. *Gastroenterology*, 142(5), pp.1140-1149.e3.
- Van Bommel F, Berg T. HBV Treatment-Standard of care in Hepatology, a clinical textbook. Duesseldorf. Flying Publisher. 2009: 119-142
- Viganò, M., Grossi, G., Loglio, A. and Lampertico, P., 2018. Treatment of hepatitis B: Is there still a role for interferon?. *Liver International*, 38, pp.79-83.
- Wang, Y., Yang, S., Su, C., Wang, Y., Lee, K., Huo, T., Lin, H. and Huang, Y. (2016). Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. *Scientific Reports*, 6(1).
- Who.int. 2020. *Hepatitis B*. [online] Available at: <<https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>> [Accessed 22 February 2020].
- Woo, A., Kwok, R. and Ahmed, T. (2017). Alpha-interferon treatment in hepatitis B. *Annals of Translational Medicine*, 5(7), pp.159-159.
- Xie, F., Yan, L., Lu, J., Zheng, T., Shi, C., Ying, J., Shen, R. and Yang, J., 2013. Effects of Nucleoside Analogue on Patients with Chronic Hepatitis B-Associated Liver Failure: Meta-Analysis. *PLoS ONE*, 8(1), p.e54773.
- Xu, F., Song, H., Li, N. and Tan, G., 2016. HBsAg blocks TYPE I IFN induced up-regulation of A3G through inhibition of STAT3. *Biochemical and Biophysical Research Communications*, 473(1), pp.219-223.
- Yang, F., Yin, Y., Wang, F., Zhang, L., Wang, Y. and Sun, S., 2010. An Altered Pattern of Liver Apolipoprotein A-I Isoforms Is Implicated in Male Chronic Hepatitis B Progression. *Journal of Proteome Research*, 9(1), pp.134-143.
- Yano, Y., Utsumi, T. and Lusida, M. (2015). Hepatitis B virus infection in Indonesia. *World Journal of Gastroenterology*, 21(38), p.10714.
- Zhang, W., Zhang, D., Dou, X., Xie, Q., Jiang, J., Chen, X. and Ren, H. (2018). Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. *Journal of Clinical and Translational Hepatology*, 6(1), pp.1-10